Megan Hardin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Megan Hardin has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Juby Anne Jacob-Nara
Sanofi
6 shared publications - Alberto Papi
University of Ferrara, S. Anna University Hospital, Ferrara, Italy
5 shared publications - Christian Domingo
Department of Pulmonary Medicine, Parc Taulí Hospital Universitari, Institut d’Investigació i Innovació Parc Taulí (I3PT-CERCA), Universitat Autònoma de Barcelona, Sabadell, Spain
5 shared publications - Ian Douglas Pavord
Respiratory Medicine Unit and Oxford Respiratory NIHR BRC, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK
5 shared publications - Arnaud Bourdin
Department of Respiratory Diseases, Montpellier University Hospital, Arnaud de Villeneuve Hospital, Montpellier, France
4 shared publications - Jorge Fernando Maspero
Fundación Cidea, Buenos Aires, ARGENTINA
4 shared publications
Latest Publications
- Open Access
- 1 June 2024
- Published by Taylor & Francis in Journal of Asthma and Allergy
- Vol. ume 17, 551-556
Baseline Systemic Oral Corticosteroid Use in Patients with Asthma Initiating Dupilumab Treatment in the Real World: From the RAPID Global Registry
The objective of the RAPID registry is to collect information on use of asthma therapy and the long-term effectiveness and safety of dupilumab for asthma.
- 1 June 2024
- Published by Taylor & Francis in Journal of Asthma and Allergy
- Vol. ume 17, 551-556
Open AccessBaseline Systemic Oral Corticosteroid Use in Patients with Asthma Initiating Dupilumab Treatment in the Real World: From the RAPID Global Registry
The objective of the RAPID registry is to collect information on use of asthma therapy and the long-term effectiveness and safety of dupilumab for asthma.
- Open Access
- 15 April 2024
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 209 (8) , 1031-1033
Biomarkers Associated with Lung Function Decline and Dupilumab Response in Patients with Asthma
- 15 April 2024
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 209 (8) , 1031-1033
Open AccessBiomarkers Associated with Lung Function Decline and Dupilumab Response in Patients with Asthma
- Open Access
Dupilumab sustains efficacy in patients with moderate‐to‐severe type 2 asthma regardless of inhaled corticosteroids dose
Background: Dupilumab, a human monoclonal antibody, blocks the shared receptor component for interleukins‐4/13, key and central drivers of type 2 inflammation. The TRAVERSE (NCT02134028) open‐label extension study demonstrated the long‐term safety and efficacy of dupilumab in patients ≥12 years who completed a previous dupilumab asthma study. The safety profile was consistent with that observed in the parent studies. Here, we assess whether dupilumab sustains long‐term efficacy in patients regardless of inhaled corticosteroid (ICS) dose at parent study baseline (PSBL).Methods: Patients from phase 2b (NCT01854047) or phase 3 (QUEST; NCT02414854) studies receiving high‐ or medium‐dose ICS at PSBL and enrolled in TRAVERSE were included. We analyzed unadjusted annualized severe exacerbation rates, change from PSBL in pre‐bronchodilator (BD) forced expiratory volume in 1 second (FEV1), 5‐item asthma control questionnaire, and type 2 biomarkers in patients with type 2 asthma at baseline (blood eosinophils ≥150 cells/μL or fractional exhaled nitric oxide [FeNO] ≥25 ppb), and subgroups defined by baseline blood eosinophils or FeNO.Results: Of patients with type 2 asthma (n = 1666), 891 (53.5%) were receiving high‐dose ICS at PSBL. In this subgroup, unadjusted exacerbation rates for dupilumab versus placebo were 0.517 versus 1.883 (phase 2b) and 0.571 versus 1.300 (QUEST) over the parent study (52 weeks) and remained low throughout TRAVERSE (0.313–0.494). Improvements in pre‐BD FEV1 were sustained throughout TRAVERSE. Similar clinical efficacy was observed among patients receiving medium‐dose ICS at PSBL and biomarker subgroups.Conclusions: Dupilumab showed sustained efficacy for up to 3 years in patients with uncontrolled, moderate‐to‐severe type 2 asthma on high‐ or medium‐dose ICS.
Open AccessDupilumab sustains efficacy in patients with moderate‐to‐severe type 2 asthma regardless of inhaled corticosteroids dose
Background: Dupilumab, a human monoclonal antibody, blocks the shared receptor component for interleukins‐4/13, key and central drivers of type 2 inflammation. The TRAVERSE (NCT02134028) open‐label extension study demonstrated the long‐term safety and efficacy of dupilumab in patients ≥12 years who completed a previous dupilumab asthma study. The safety profile was consistent with that observed in the parent studies. Here, we assess whether dupilumab sustains long‐term efficacy in patients regardless of inhaled corticosteroid (ICS) dose at parent study baseline (PSBL).Methods: Patients from phase 2b (NCT01854047) or phase 3 (QUEST; NCT02414854) studies receiving high‐ or medium‐dose ICS at PSBL and enrolled in TRAVERSE were included. We analyzed unadjusted annualized severe exacerbation rates, change from PSBL in pre‐bronchodilator (BD) forced expiratory volume in 1 second (FEV1), 5‐item asthma control questionnaire, and type 2 biomarkers in patients with type 2 asthma at baseline (blood eosinophils ≥150 cells/μL or fractional exhaled nitric oxide [FeNO] ≥25 ppb), and subgroups defined by baseline blood eosinophils or FeNO.Results: Of patients with type 2 asthma (n = 1666), 891 (53.5%) were receiving high‐dose ICS at PSBL. In this subgroup, unadjusted exacerbation rates for dupilumab versus placebo were 0.517 versus 1.883 (phase 2b) and 0.571 versus 1.300 (QUEST) over the parent study (52 weeks) and remained low throughout TRAVERSE (0.313–0.494). Improvements in pre‐BD FEV1 were sustained throughout TRAVERSE. Similar clinical efficacy was observed among patients receiving medium‐dose ICS at PSBL and biomarker subgroups.Conclusions: Dupilumab showed sustained efficacy for up to 3 years in patients with uncontrolled, moderate‐to‐severe type 2 asthma on high‐ or medium‐dose ICS.
- Open Access
- 11 October 2021
- Published by BMJ
- Vol. 106 (Suppl 2) , A70
166 Efficacy of Dupilumab in Children With Uncontrolled, Moderate-to-Severe Type 2 Asthma, With and Without Evidence of Allergy Enrolled in Phase 3 VOYAGE
The allergic phenotype is an important subset of asthma patients with type 2 inflammation. Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for IL-4/IL-13, key and central drivers of type 2 inflammation in multiple diseases. In phase 3 VOYAGE, add-on dupilumab 100mg/200mg (body weight ≤30kg/>30kg, respectively) every 2 weeks vs placebo, reduced severe asthma exacerbations by 59.3% (P<0.0001) and improved lung function in children aged 6 to <12 years with uncontrolled moderate-to-severe type 2 asthma (baseline blood eosinophils ≥150cells/µl or FeNO ≥20ppb). This analysis evaluated the efficacy of dupilumab in pediatric patients with type 2 asthma with/without evidence of allergic asthma (total serum IgE ≥30IU/mL and ≥1 perennial aeroallergen-specific IgE ≥0.35kU/L at baseline). Annualized severe exacerbation rate during the 52-week treatment period was assessed using a negative binomial model. 350 pediatric patients with type 2 asthma were enrolled: of which, 261 had evidence of allergic asthma and 89 did not. Baseline characteristics were similar between subgroups, except for prevalence of ongoing atopic comorbidities (99.6% vs 77.5%) and median levels of type 2 biomarkers (blood eosinophils: 540.00cells/µL vs 310.00cells/µL; FeNO: 28ppb vs 13ppb; total serum IgE: 657.00IU/mL vs 107.00IU/mL) which were all higher in patients with vs without evidence of allergic asthma. Dupilumab vs placebo significantly reduced annualized severe exacerbation rate by 62% (P<0.0001) in patients with, and 51% (P<0.05) in patients without evidence of allergic asthma. No significant interaction was observed between the treatment effect and evidence of allergic asthma. In the overall safety population, the incidence of treatment-emergent adverse events (TEAEs) was similar across treatment groups; the most common TEAE occurring more frequently in the dupilumab group was injection site erythema (12.9% dupilumab vs 9.7% placebo). The majority of pediatric type 2 asthma patients enrolled in VOYAGE had evidence of allergic asthma; these patients had very high levels of type 2 biomarkers. Dupilumab demonstrated efficacy in reducing severe asthma exacerbations in children aged 6 to <12 years with uncontrolled, moderate-to-severe type 2 asthma, with or without evidence of allergic asthma.
- 11 October 2021
- Published by BMJ
- Vol. 106 (Suppl 2) , A70
Open Access166 Efficacy of Dupilumab in Children With Uncontrolled, Moderate-to-Severe Type 2 Asthma, With and Without Evidence of Allergy Enrolled in Phase 3 VOYAGE
The allergic phenotype is an important subset of asthma patients with type 2 inflammation. Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for IL-4/IL-13, key and central drivers of type 2 inflammation in multiple diseases. In phase 3 VOYAGE, add-on dupilumab 100mg/200mg (body weight ≤30kg/>30kg, respectively) every 2 weeks vs placebo, reduced severe asthma exacerbations by 59.3% (P<0.0001) and improved lung function in children aged 6 to <12 years with uncontrolled moderate-to-severe type 2 asthma (baseline blood eosinophils ≥150cells/µl or FeNO ≥20ppb). This analysis evaluated the efficacy of dupilumab in pediatric patients with type 2 asthma with/without evidence of allergic asthma (total serum IgE ≥30IU/mL and ≥1 perennial aeroallergen-specific IgE ≥0.35kU/L at baseline). Annualized severe exacerbation rate during the 52-week treatment period was assessed using a negative binomial model. 350 pediatric patients with type 2 asthma were enrolled: of which, 261 had evidence of allergic asthma and 89 did not. Baseline characteristics were similar between subgroups, except for prevalence of ongoing atopic comorbidities (99.6% vs 77.5%) and median levels of type 2 biomarkers (blood eosinophils: 540.00cells/µL vs 310.00cells/µL; FeNO: 28ppb vs 13ppb; total serum IgE: 657.00IU/mL vs 107.00IU/mL) which were all higher in patients with vs without evidence of allergic asthma. Dupilumab vs placebo significantly reduced annualized severe exacerbation rate by 62% (P<0.0001) in patients with, and 51% (P<0.05) in patients without evidence of allergic asthma. No significant interaction was observed between the treatment effect and evidence of allergic asthma. In the overall safety population, the incidence of treatment-emergent adverse events (TEAEs) was similar across treatment groups; the most common TEAE occurring more frequently in the dupilumab group was injection site erythema (12.9% dupilumab vs 9.7% placebo). The majority of pediatric type 2 asthma patients enrolled in VOYAGE had evidence of allergic asthma; these patients had very high levels of type 2 biomarkers. Dupilumab demonstrated efficacy in reducing severe asthma exacerbations in children aged 6 to <12 years with uncontrolled, moderate-to-severe type 2 asthma, with or without evidence of allergic asthma.
- 7 September 2020
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (suppl 64) , 4613
Late Breaking Abstract - Dupilumab long-term safety and efficacy in patients with asthma: LIBERTY ASTHMA TRAVERSE
Introduction: Dupilumab (DPL), a fully human mAb, blocks the shared receptor component for IL‑4/IL‑13. The efficacy and safety of DPL in asthma have been demonstrated up to 52 wks in phase (P) 2/3 studies. Aim: This open-label extension (OLE) study (NCT02134028) assessed long-term safety and efficacy of DPL in adult and adolescent patients (pts) who had completed a DPL asthma study (P2b DRI, P2 EXPEDITION, P3 QUEST or VENTURE). Methods: 2282 moderate-to-severe asthma or OCS-dependent severe asthma pts received add‑on SC DPL 300mg every 2 wks up to 96 wks. Treatment-emergent adverse events (TEAE), annualized rate of severe asthma exacerbations (AER) during the treatment period, and change from parent study baseline (BL) in FEV1 and biomarkers up to Wk 96 were assessed. Results: 2039 pts completed the OLE treatment period with a safety profile that was consistent with the shorter-duration parent studies (Table). The low unadjusted AER and improvement in FEV1 observed in the parent studies were sustained during the OLE. Similar efficacy was seen in pts with elevated type 2 biomarkers from DRI/QUEST. By Wk 96, blood eosinophils decreased to below-parent study BL levels in pts from DRI/QUEST and were near-parent study BL levels in pts from VENTURE; total IgE levels decreased by 82% (median % change from parent BL). Conclusion: Long-term use of dupilumab was well tolerated and showed sustained efficacy in asthma pts up to 96 wks.
- 7 September 2020
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (suppl 64) , 4613
Late Breaking Abstract - Dupilumab long-term safety and efficacy in patients with asthma: LIBERTY ASTHMA TRAVERSE
Introduction: Dupilumab (DPL), a fully human mAb, blocks the shared receptor component for IL‑4/IL‑13. The efficacy and safety of DPL in asthma have been demonstrated up to 52 wks in phase (P) 2/3 studies. Aim: This open-label extension (OLE) study (NCT02134028) assessed long-term safety and efficacy of DPL in adult and adolescent patients (pts) who had completed a DPL asthma study (P2b DRI, P2 EXPEDITION, P3 QUEST or VENTURE). Methods: 2282 moderate-to-severe asthma or OCS-dependent severe asthma pts received add‑on SC DPL 300mg every 2 wks up to 96 wks. Treatment-emergent adverse events (TEAE), annualized rate of severe asthma exacerbations (AER) during the treatment period, and change from parent study baseline (BL) in FEV1 and biomarkers up to Wk 96 were assessed. Results: 2039 pts completed the OLE treatment period with a safety profile that was consistent with the shorter-duration parent studies (Table). The low unadjusted AER and improvement in FEV1 observed in the parent studies were sustained during the OLE. Similar efficacy was seen in pts with elevated type 2 biomarkers from DRI/QUEST. By Wk 96, blood eosinophils decreased to below-parent study BL levels in pts from DRI/QUEST and were near-parent study BL levels in pts from VENTURE; total IgE levels decreased by 82% (median % change from parent BL). Conclusion: Long-term use of dupilumab was well tolerated and showed sustained efficacy in asthma pts up to 96 wks.